Glucose MetabolismNCT06921824
Investigating the Acute Effects of Increasing Glucagon Exposure in Healthy Participants
A study testing Glucagon in people with Glucose Metabolism and Glucagon, run by Nicolai Jacob Wewer Albrechtsen at 1 site in Denmark.
Trial summary
In this study the investigators will investigate the acute effects of increasing glucagon exposure on metabolic parameters in healthy participants. Participants will participate in one study day. After initial baseline blood samples, a three-hour intravenous infusion with glucagon will be initiated. Read more about this study
- Who is it for?
- Ages 25 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Glucose Metabolism, Glucagon
- What is being tested?
- Glucagon
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- 1 siteDenmark
- Study dates
- 31 Mar 2025to 19 Sep 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Capable of understanding the participant information and signing the consent form
- Between 25 and 70 years of age at the time of screening
- Body mass index (BMI) ≤ 25 kg/m2 at the time of screening
Who cannot join
- Enrolment in other research projects that might interfere with the study
- Diabetes diagnosis (type 1 and 2)
- Pregnancy or breastfeeding
- Use of medications which, in the opinion of the investigator, may jeopardise participant's safety or compliance with the protocol
- Impaired liver function defined as either alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) ≥ 2 times normal values
- Kidney disease defined as serum creatinine levels ≥ 126 μmol/L for male and ≥ 111 μmol/L for female
Show all 10Show fewer
- Inadequately treated blood pressure at screening defined as repeated resting blood pressure outside the range 90-150 mmHg for systolic and 50-100 mmHg for diastolic
- Active or recent malignant disease
- Current or history of severe alcohol use or drug/chemical abuse as per investigator's judgement
- Any chronic disorders or severe diseases which, in the opinion of the investigator, might jeopardise participant's safety or compliance with the protocol
Trial locations and contacts
1 site in 1 country.
Denmark1 site
Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark
Copenhagen, 2400
About this study
Official title: Investigating the Effect of Glucagon on Cognitive Function and Cerebral Glucose Metabolism in Humans: A Pilot Study
In this study the investigators will investigate the acute effects of increasing glucagon exposure on metabolic parameters in healthy participants.
Participants will participate in one study day. After initial baseline blood samples, a three-hour intravenous infusion with glucagon will be initiated. The infusion rate will be increased every 30 minutes.
Read the detailed description
Ten participants with normal health will be included, and each participant will participate in one study day.
Participants will arrive after an overnight fast and will be placed in a hospital bed in a semi-recumbent position. In each antecubital vein an intravenous catheter will be placed; one for administration of glucagon and one for blood sampling.
Two baseline blood samples will be drawn before the glucagon infusion is started. The glucagon infusion rate will be increased every 30 minutes (infusion rates are 0,01 ng/kg/min, 0,1 ng/kg/min, 0,5 ng/kg/min, 1,0 ng/kg/min, 10 ng/kg/min and 50 ng/kg/min).
Blood samples for the analysis of plasma glucagon, glucose, insulin, C-peptide etc. will be drawn every 15 minutes.
- Conditions
- Glucose Metabolism, Glucagon
- Being tested
- Glucagon
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GlucagonOther
A three-hour intravenous infusion with glucagon with increasing infusion rate (from 0,01 ng/kg/min up to 50 ng/kg/min)
| Study group | Role | What they receive |
|---|---|---|
| Glucagon Infusion | Experimental | Not described Receives: Other: Glucagon |
What is being measured
The primary outcome is the main question the study is designed to answer.
Glucagon infusion rate that increases plasma glucose
Glucagon infusion rate at which plasma glucose levels are significantly increased compared to baseline
Measured: 0-180 minutes
Secondary outcomes (4)
Glucagon infusion rate that increases plasma cAMP
Glucagon infusion rate at which plasma cAMP levels are significantly increased compared to baseline
Measured: 0-180 minutes
Glucagon infusion rate that decreases plasma amino acids
Glucagon infusion rate at which plasma amino acid levels are significantly decreased compared to baseline
Measured: 0-180 minutes
Glucagon infusion rate that affects plasma triglycerides
Glucagon infusion rate at which plasma triglycerides are significantly changed compared to baseline
Measured: 0-180 minutes
Glucagon infusion rate that affects plasma nonesterified fatty acids
Glucagon infusion rate at which plasma nonesterified fatty acids are significantly changed compared to baseline
Measured: 0-180 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Apr 2025
- Study start31 Mar 2025
- Primary completion19 Sep 2025
- Study completion19 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Glucose MetabolismStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- Nicolai Jacob Wewer Albrechtsen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Nicolai Jacob Wewer Albrechtsen, University of Copenhagen
- Investigators
- Nicolai J Wewer Albrecthsen, MD PhD, Principal investigator, Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06921824
- Sponsor's protocol ID
- GluCoMet_stepwise glucagon
- Status last verified
- Dec 2025
- First submitted
- 3 Apr 2025
- Last updated
- 24 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigating the Effect of Glucagon on Cognitive Function and Cerebral Glucose Metabolism in Humans: A Pilot Study
- ClinicalTrials.gov ID
- NCT06921824
- Acronym / sponsor ID
- GluCoMet_stepwise glucagon
- Conditions
- Glucose Metabolism, Glucagon
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- Nicolai Jacob Wewer AlbrechtsenUniversity, hospital or other
- Study start
- 31 Mar 2025 (actual)
- Primary completion
- 19 Sep 2025 (actual)
- Study completion
- 19 Sep 2025 (actual)
- First posted
- 10 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this study the investigators will investigate the acute effects of increasing glucagon exposure on metabolic parameters in healthy participants.
Participants will participate in one study day. After initial baseline blood samples, a three-hour intravenous infusion with glucagon will be initiated. The infusion rate will be increased every 30 minutes.
Detailed description
Ten participants with normal health will be included, and each participant will participate in one study day.
Participants will arrive after an overnight fast and will be placed in a hospital bed in a semi-recumbent position. In each antecubital vein an intravenous catheter will be placed; one for administration of glucagon and one for blood sampling.
Two baseline blood samples will be drawn before the glucagon infusion is started. The glucagon infusion rate will be increased every 30 minutes (infusion rates are 0,01 ng/kg/min, 0,1 ng/kg/min, 0,5 ng/kg/min, 1,0 ng/kg/min, 10 ng/kg/min and 50 ng/kg/min).
Blood samples for the analysis of plasma glucagon, glucose, insulin, C-peptide etc. will be drawn every 15 minutes.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Glucagon Infusion | Experimental | Other: Glucagon |
Who may qualify
- Ages
- 25 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Capable of understanding the participant information and signing the consent form
- Between 25 and 70 years of age at the time of screening
- Body mass index (BMI) ≤ 25 kg/m2 at the time of screening
Key exclusion criteria (10 listed)
- Enrolment in other research projects that might interfere with the study
- Diabetes diagnosis (type 1 and 2)
- Pregnancy or breastfeeding
- Use of medications which, in the opinion of the investigator, may jeopardise participant's safety or compliance with the protocol
- Impaired liver function defined as either alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) ≥ 2 times normal values
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GlucagonA three-hour intravenous infusion with glucagon with increasing infusion rate (from 0,01 ng/kg/min up to 50 ng/kg/min) | Other | Glucagon Infusion |
Primary outcome
Glucagon infusion rate that increases plasma glucose
Time frame: 0-180 minutes
Glucagon infusion rate at which plasma glucose levels are significantly increased compared to baseline
4 secondary outcomes
Glucagon infusion rate that increases plasma cAMP
Time frame: 0-180 minutes
Glucagon infusion rate that decreases plasma amino acids
Time frame: 0-180 minutes
Glucagon infusion rate that affects plasma triglycerides
Time frame: 0-180 minutes
Glucagon infusion rate that affects plasma nonesterified fatty acids
Time frame: 0-180 minutes
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Dec 2025.
Related trials for Glucose Metabolism
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Recruiting
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
Hyperglycaemia (Non Diabetic), Prediabetes
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nicolai J Wewer Albrecthsen, MD PhD principal investigator
Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Glucagon in people with Glucose Metabolism and Glucagon, run by Nicolai Jacob Wewer Albrechtsen at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Glucagon infusion rate that increases plasma glucose (time frame: 0-180 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Dec 2025.